Table II.
Cycle characteristics and outcomes of FET cycles in G-CSF cotreated treated and control groups
| Variables | G-CSF cotreated group (n=34) | Control group (n= 34) | p-value | |
|---|---|---|---|---|
| No. of Transferred embryos | 2.46 ± 0.63 | 2.39 ± 0.49 | 0.64 | |
| Embryo quality | ||||
| A | 20 (71.40% | 17 (60.70%) | 0.57 | |
| B | 8 (28.60%) | 11 (39.30%) | ||
| Cycle cancellation | 5 (15.20%) | 5 (15.20%) | 1.00 | |
| Endometrial thickness, (mm) at | ||||
| D1 | 5.63 ± 0.78 | 5.76 ± 0.86 | 0.88 | |
| D2 | 7.91 ± 0.55 | 8.23 ± 0.82 | 0.10 | |
| Chemical pregnancy | 11 (39.30%) | 4 (14.30%) | 0.68 | |
| Clinical pregnancy | 9 (32.10%) | 3(12%) | 0.10 | |
G-CSF: granulocyte colony-stimulating factor
FET: frozen embryo transfer
D1: endometrial thickness at the 12th-13th day of frozen- thawed embryo transfer cycle
D2: endometrial thickness at the first day of progesterone injection
Transfer dayx: The frozen- thawed cycle day which the embryos were transferred
Continuous data presented as mean±SD with p-values obtained from Independent-Samples T test; Enumerationl data presented as N (%) with p-value obtained from Chi-Square or fisher exact test. A p-value of<0.05 was considered statistically significant.